Toggle light / dark theme

The team plans to keep studying whether vaccines could help alleviate IBD symptoms, which tend to stay dormant then flare up. They also hope to find similar ways to nudge a dysfunctional gut microbiome back into balance.


The connection between gut bacteria and our overall health has been well studied in recent years. And while many of the specifics of this relationship are still unknown, it’s clear that a balanced microbiome with the right mix of bacteria helps maintain many of our regular bodily functions; conversely, the wrong mix of bacteria might help cause or signal the emergence of illness. But bacteria are only one type of microbe, and there’s been less work studying the many viruses and fungi that inhabit our body.

This new research was conducted by scientists from the University of Utah Health, who were curious if fungi were relevant to the development of inflammatory bowel disease (IBD), which includes Crohn’s. IBD is a complicated disorder, thought to have several contributing factors, including genetics. But recent research has suggested that certain species of fungi and yeast (the single celled version of fungi) could be one of these risk factors, including a common fungi in our gut called Candida albicans.

In experiments with mice, the team noticed that a functioning immune system seemed to interact with C. albicans. The yeast has the uncanny ability to switch between different forms of growth. It can remain a ball-like single-celled organism, or it can turn into a multicellular form, decked out with hyphae, a common branch-like structure found in most other fungi, that allows it to invade the tissues of our body to keep growing. The team found evidence that antibodies specific to C. albicans didn’t outright try to kill it—instead, they kept the yeast from turning into this more invasive form. But once the yeast was allowed to grow unfettered, the mice became sick with IBD-like symptoms, which can include diarrhea, intense cramps, and weight loss.

“The trend for feeding dogs raw food may be fuelling the spread of antibiotic resistant-bacteria”, the researchers said in a press release for their study, to be presented at the European Congress of Clinical Microbiology & Infectious Diseases.

Separate research to be presented at the same conference found resistance to a last-resort antibiotic may be passing between pet dogs and their owners.


Antibiotic-resistant “superbugs” — which the World Health Organization calls one of the top global threats to public health — usually conjure images of hospital settings.

A new wearable device turns the touch of a finger into a source of power for small electronics and sensors. Engineers at the University of California San Diego developed a thin, flexible strip that can be worn on a fingertip and generate small amounts of electricity when a person’s finger sweats or presses on it.

What’s special about this sweat-fueled device is that it generates power even while the wearer is asleep or sitting still. This is potentially a big deal for the field of wearables because researchers have now figured out how to harness the energy that can be extracted from human sweat even when a person is not moving.

This type of device is the first of its kind, said co-first author Lu Yin, a nanoengineering Ph.D. student at the UC San Diego Jacobs School of Engineering. “Unlike other sweat-powered wearables, this one requires no exercise, no physical input from the wearer in order to be useful. This work is a step forward to making wearables more practical, convenient and accessible for the everyday person.”

The formula for launching a machine learning company in health care looks something like this: Build a model, test it on historical patient data in a computer lab, and then start selling it to hospitals nationwide.

Suchi Saria, director of the machine learning and health care lab at Johns Hopkins University, is taking a different approach. Her company, Bayesian Health, is coming out of stealth mode on Monday by publishing a prospective study on how one of its lead products — an early warning system for sepsis — impacted the care of current patients in real hospitals.

To develop its drug, Vir “deliberately isolated an antibody that binds to a part of the virus that is very difficult for the virus to mutate,” he said. That piece of the virus is “conserved, not only in all the variants, but in SARS-1… and in a whole family of coronaviruses.”

Vir knew the variant onslaught was coming, said the company’s executive vice president of research and chief scientific officer, Herbert “Skip” Virgin, M.D., Ph.D. So far, added Scangos, its premise of targeting a conserved site to maintain efficacy against mutations “seems to be holding true.”

Sotrovimab “appears to retain activity against variants of concern” like alpha, beta, gamma, epsilon and iota, the National Institutes of Health noted in recently updated COVID-19 treatment guidelines. Last week, GSK and Vir provided data suggesting that delta also belongs to that list. Updated lab experiment data posted on the preprint repository bioRxiv showed sotrovimab’s activity against 14 variants including the troubling delta variant—which first surfaced in India and appears to spread more rapidly than the already-speedy alpha—was very similar to that against the original SARS-CoV-2 virus.


While several vaccines now stand tall in the fight against COVID-19, therapies—and antibody drugs in particular—have had a decidedly tougher time. Saddled with access issues and beset by fast-emerging variants, firstcomer Eli Lilly has recently been forced to rethink its tactics. Now, GlaxoSmithKline and Vir Biotechnology are applying those lessons to their solo agent sotrovimab.

Backed by promising phase 3 data and lab results showing efficacy against a suite of virus variants including the lurking delta variant, sotrovimab still has a big role to play in the pandemic, executives from GSK and Vir said in a recent joint interview with Fierce Pharma and Fierce Biotech.

Federal officials seem to agree. Late last week, the U.S. paused the distribution of Eli Lilly’s combo of bamlanivimab and etesevimab until further notice, citing the ascent of the gamma and beta variants stateside. With Lilly’s drug struggling to keep pace with mutations, the Assistant Secretary for Preparedness Response and the FDA urged healthcare providers to switch to other authorized antibodies like sotrovimab and Regeneron’s cocktail REGEN-COV, both of which are “likely to retain activity” against the gamma and beta variants, which now make up more than 11% of sequenced U.S. coronavirus cases, ASPR said in a release.

Safe and readily available water is important for public health, whether it is used for drinking, domestic use, food production, or recreational purposes. Despite the vast quantity of water on Earth, just 2.5% of it is freshwater, and an estimated 785 million people lack a clean source of drinking water. Desalination of seawater could be a vital technology to meet the world’s drinking water needs.

Now, Korean engineers have developed a new desalination technique that takes just minutes to make seawater drinkable. They used a new nanofiber membrane distillation process that could desalinate water with 99.99% efficiency. Engineers believe that commercializing such technology could help humankind cope with the shortage of fresh drinking water in the future.

Amongst the most challenging issues in membrane distillation is membrane wetting that causes the pollution of permeate, reduction in vapor production, and finally, reduction in the performance of the membrane. If a membrane exhibits wetting during membrane distillation operation, the membrane must be replaced.

A previous study led by Lee found losing just 16 minutes of sleep could impact job performance. Her previous findings also show that minor sleep loss can decrease daily mindfulness, which is a critical recourse for managing stress and maintaining healthy routines.


Summary: Three consecutive nights of sleep loss can have a negative impact on both mental and physical health. Sleep deprivation can lead to an increase in anger, frustration, and anxiety. Additionally, those who experienced sleep loss reported a change in physical wellbeing, including gastrointestinal and respiratory problems.

Source: USF

All it takes is three consecutive nights of sleep loss to cause your mental and physical well-being to greatly deteriorate.

A new study published in Annals of Behavioral Medicine looked at the consequences of sleeping fewer than six hours for eight consecutive nights – the minimum duration of sleep that experts say is necessary to support optimal health in average adults.

This mapping of aetiological sources of cross-disorder overlap can guide future research aiming to identify specific mechanisms contributing to risk of physical conditions in people with ADHD, which could ultimately inform preventive and lifestyle intervention efforts. Our findings highlight the importance of assessing the presence of physical conditions in patients with ADHD.

Swedish Research Council; Swedish Brain Foundation; Swedish Research Council for Health, Working Life, and Welfare; Stockholm County Council; StratNeuro; EU Horizon 2020 research and innovation programme; National Institute of Mental Health.